Cebranopadol, a Novel Potent Analgesic: Limitations in Physical Dependence Using Short- and Long-term Rodent Studies (PAINWeek 2022) - Sep 19, 2022 - Abstract #22; "Cebranopadol is a highly potent analgesic with efficacy demonstrated across a variety of pain types and animal models at effective doses (ED 50 ) ranging from 0.5-5.6 μg/kg. Spontaneous and precipitated withdrawal following cebranopadol administration was limited demonstrating a low potential for cebranopadol to lead to physical dependence in rodents despite supratherapeutic doses. Clinical studies have demonstrated consistent results in humans."
Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Pain • Psychiatry
|
|
David Fam, PharmD; Marc Lesnick, PhD; James Hackworth, PhD
|